The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
Participants must have an unresectable/metastatic carcinoma.
Participants must not have Leptomeningeal metastases.
Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
Other protocol-defined Inclusion/Exclusion criteria apply.
Sequential
BMS-986463
DrugSpecified dose on specified days
Number of participants with adverse events (AEs)
Number of participants with serious adverse events (SAEs)
Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) criteria
Number of participants with AEs leading to discontinuation
Maximum observed concentration (Cmax)
Area under the concentration-time curve (AUC)
Time of maximum observed concentration (Tmax)
Objective response rate (ORR)
Click on the lead sponsor to view all of their trials.
